Celldex Therapeutics Statistics
NASDAQ: CLDXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
30.43-0.575 (-1.85%)
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Celldex Therapeutics by the numbers
Celldex Therapeutics has a market capitalization of $2.39 billion based on 78.53M shares outstanding. With trailing EPS of $-4.27, Celldex Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 20.2% below its 50-day average and 6.1% below its 200-day average.
Average daily trading volume is 1.26M shares, or about $38.4 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
CLDX valuation vs. peer median
| Metric | CLDX | Peer median | Difference |
|---|---|---|---|
| Market cap | $2.39B | $48.40M | +4838% |
| Avg. volume | 1.26M | 152.93K | +726% |
Peer median across 8 companies: NEOG, NTLA, IMDX, ICCC, BMRA, VNRX, CDIO, TRIB.
Valuation
- Market cap
- $2.39B
- Price / sales (latest FY)
- 1,546.70
- EPS (TTM)
- $-4.27
- Shares outstanding
- 78.53M
Price and trading
- Previous close
- 31.01
- Open
- 30.62
- Day range
- 30.11 – 31.35
- 52-week range
- 22.10 – 45.14
- 52-week change
- +16.06%
- Beta
- —
- Volume
- 1.75M
- Average volume
- 1.26M
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 9, 2026
Additional statistics
- Market Cap
- 2.39B
- Forward Pe
- -7.18
- Eps
- -4.27
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 45.14
- Week52 Low
- 22.10
- Avg Volume
- 1.26M
- Shares Outstanding
- 78.53M
- Ma50
- 38.14
- Ma200
- 32.39
- Earnings Date
- Nov 9, 2026
- Pct From52w High
- -32.59%
- Pct From52w Low
- 37.69%